orphan status won't mean much. the drug has yet to fully prove itself in clinical trials. DARA has not done a good job fully defining the size of the market for this drug which is an infusion product. Too much unknown. Too many people DO NOT understand what orphan means. It does not mean "automatic $$$$$". Just look at Savient where they have been selling an "orphan" drug for nearly two years and the stock in languishing at $1.
Stop the orphan nonsense and hope this company generates revenue on the products it licensed in....
It doesn't mean anything to DARA? Yeah ok. That space KRN5500 is getting in will be in the BILLIONS of dollars and ZERO competition. You better read up some more! And don't compare junk SVNT with DARA and it's pipeline ok.
To be clear Kerx went from the low $3's to just shy of $10. I should know I profited in that range, although I sold short of the day it crossed $8's. Talking about leaving money on the table. It's one to watch in the next 6 - 9 months. PDAFU play and also Phase II predialysis results toward the end of 2013, that' s if they aren't bought or partner prior to both events. I think it will settle above $8, maybe $7.50. The have an opportunity to get 50% on the above items.